Tarsus Pharmaceuticals, Inc. (TARS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Irvine, CA, United States. Der aktuelle CEO ist Bobak R. Azamian.
TARS hat IPO-Datum 2020-10-16, 323 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $3.14B.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Irvine, California, focused on developing novel therapeutic candidates for ophthalmic and dermatological conditions. The company's lead product candidate, TP-03, is in Phase III clinical trials for treating blepharitis caused by Demodex mite infestation and meibomian gland disease. Tarsus is also advancing a pipeline that includes TP-04 for rosacea treatment and TP-05 for Lyme disease prophylaxis and malaria reduction, alongside the development of lotilaner for multiple therapeutic applications across ophthalmology, dermatology, and other disease areas. Founded in 2016, the company is positioned to address significant unmet medical needs in eye care and skin conditions.
